Compagnie Lombard Odier SCmA’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $190K | Hold |
11,000
| – | – | ﹤0.01% | 243 |
|
|
2025
Q1 | $241K | Hold |
11,000
| – | – | ﹤0.01% | 241 |
|
|
2024
Q4 | $351K | Hold |
11,000
| – | – | 0.01% | 201 |
|
|
2024
Q3 | $317K | Hold |
11,000
| – | – | ﹤0.01% | 207 |
|
|
2024
Q2 | $422K | Buy |
11,000
+7,000
| +175% | +$269K | 0.01% | 191 |
|
|
2024
Q1 | $235K | Hold |
4,000
| – | – | ﹤0.01% | 242 |
|
|
2023
Q4 | $239K | Hold |
4,000
| – | – | ﹤0.01% | 266 |
|
|
2023
Q3 | $152K | Hold |
4,000
| – | – | ﹤0.01% | 308 |
|
|
2023
Q2 | $364K | Hold |
4,000
| – | – | 0.01% | 195 |
|
|
2023
Q1 | $264K | Sell |
4,000
-500
| -11% | -$33K | 0.01% | 250 |
|
|
2022
Q4 | $233K | Hold |
4,500
| – | – | 0.01% | 272 |
|
|
2022
Q3 | $307K | Sell |
4,500
-4,500
| -50% | -$307K | 0.01% | 254 |
|
|
2022
Q2 | $407K | Hold |
9,000
| – | – | 0.01% | 222 |
|
|
2022
Q1 | $457K | Hold |
9,000
| – | – | 0.01% | 216 |
|
|
2021
Q4 | $426K | Hold |
9,000
| – | – | 0.01% | 261 |
|
|
2021
Q3 | $297K | Hold |
9,000
| – | – | 0.01% | 304 |
|
|
2021
Q2 | $569K | Sell |
9,000
-376,795
| -98% | -$23.8M | 0.01% | 212 |
|
|
2021
Q1 | $16.6M | Buy |
385,795
+382,795
| +12,760% | +$16.4M | 0.36% | 56 |
|
|
2020
Q4 | $172K | Buy |
+3,000
| New | +$172K | ﹤0.01% | 340 |
|